Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has provided an announcement.
On August 7, 2025, NeOnc Technologies Holdings, Inc. announced it received $2.5 million in NIH STTR grants to further develop its therapeutic compound NEO212 for gliomas and leukemia. This funding supports NeOnc’s clinical momentum as it nears the completion of Phase 1 trials for NEO212, marking a significant step towards Phase 2 trials. Additionally, on August 11, 2025, the company announced the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market, potentially expanding its market reach.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of central nervous system therapeutics. The company focuses on overcoming the challenges of the blood-brain barrier with its NEO™ drug development platform, which includes novel drug candidates and delivery methods. NeOnc’s portfolio, protected by patents until 2038, is advancing through clinical trials, particularly for malignant gliomas, under FDA Fast-Track and Investigational New Drug status.
Average Trading Volume: 207,129
Technical Sentiment Signal: Strong Buy
For a thorough assessment of NTHI stock, go to TipRanks’ Stock Analysis page.